{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Escalation+of+Placebo&page=2",
    "query": {
      "intervention": "Dose Escalation of Placebo",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 990,
    "total_pages": 99,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Escalation+of+Placebo&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Escalation+of+Placebo&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T20:04:28.171Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02659800",
      "title": "Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphopenia",
        "Malignant Glioma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "NT-I7",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2018-10-30",
      "completion_date": "2023-10-03",
      "has_results": false,
      "last_update_posted_date": "2023-10-06",
      "last_synced_at": "2026-10-05T20:04:28.171Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02659800"
    },
    {
      "nct_id": "NCT03860571",
      "title": "Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Normal Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "BT-11",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NImmune Biopharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 70,
      "start_date": "2018-07-06",
      "completion_date": "2018-12-13",
      "has_results": false,
      "last_update_posted_date": "2023-06-07",
      "last_synced_at": "2026-10-05T20:04:28.171Z",
      "location_count": 1,
      "location_summary": "Blacksburg, Virginia",
      "locations": [
        {
          "city": "Blacksburg",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03860571"
    },
    {
      "nct_id": "NCT01867671",
      "title": "Peanut Oral Immunotherapy in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peanut Hypersensitivity"
      ],
      "interventions": [
        {
          "name": "Peanut Oral Immunotherapy - Liquid Extract",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for Peanut Oral Immunotherapy - Liquid Extract form",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Peanut Oral Immunotherapy - Peanut Flour",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for Peanut Oral Immunotherapy - Peanut Flour",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "48 Months",
        "sex": "ALL",
        "summary": "12 Months to 48 Months"
      },
      "enrollment_count": 146,
      "start_date": "2013-08-13",
      "completion_date": "2018-12-21",
      "has_results": true,
      "last_update_posted_date": "2020-03-16",
      "last_synced_at": "2026-10-05T20:04:28.171Z",
      "location_count": 5,
      "location_summary": "Little Rock, Arkansas • Stanford, California • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01867671"
    },
    {
      "nct_id": "NCT02030301",
      "title": "Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Genital Herpes Simplex Type 2"
      ],
      "interventions": [
        {
          "name": "VCL-HB01",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VCL-HM01",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PBS",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 165,
      "start_date": "2013-12",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2019-02-27",
      "last_synced_at": "2026-10-05T20:04:28.171Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02030301"
    },
    {
      "nct_id": "NCT02889367",
      "title": "A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Odalasvir 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Odalasvir 500 mg",
          "type": "DRUG"
        },
        {
          "name": "Odalasvir (Up to maximum 1000 mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 60,
      "start_date": "2016-09-12",
      "completion_date": "2017-03-04",
      "has_results": false,
      "last_update_posted_date": "2017-04-10",
      "last_synced_at": "2026-10-05T20:04:28.171Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02889367"
    },
    {
      "nct_id": "NCT03646721",
      "title": "A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "DA-1241",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dong-A ST Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 108,
      "start_date": "2018-08-29",
      "completion_date": "2020-05-07",
      "has_results": false,
      "last_update_posted_date": "2021-02-11",
      "last_synced_at": "2026-10-05T20:04:28.171Z",
      "location_count": 4,
      "location_summary": "Chula Vista, California • Miami, Florida • High Point, North Carolina + 1 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "High Point",
          "state": "North Carolina"
        },
        {
          "city": "Renton",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03646721"
    },
    {
      "nct_id": "NCT05846009",
      "title": "A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Osteochondrodysplasia"
      ],
      "interventions": [
        {
          "name": "SAR442501",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 76,
      "start_date": "2020-11-18",
      "completion_date": "2022-01-12",
      "has_results": false,
      "last_update_posted_date": "2024-08-27",
      "last_synced_at": "2026-10-05T20:04:28.171Z",
      "location_count": 1,
      "location_summary": "Newark, New Jersey",
      "locations": [
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05846009"
    },
    {
      "nct_id": "NCT00071409",
      "title": "Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Insulin-Dependent"
      ],
      "interventions": [
        {
          "name": "INGAP-Peptide",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exsulin Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 63,
      "start_date": "2003-10",
      "completion_date": "2004-05",
      "has_results": false,
      "last_update_posted_date": "2014-07-11",
      "last_synced_at": "2026-10-05T20:04:28.171Z",
      "location_count": 10,
      "location_summary": "Irvine, California • San Diego, California • Walnut Creek, California + 6 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00071409"
    },
    {
      "nct_id": "NCT00851734",
      "title": "A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "voclosporin ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lux Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 35,
      "start_date": "2009-02",
      "completion_date": "2009-04",
      "has_results": false,
      "last_update_posted_date": "2012-06-22",
      "last_synced_at": "2026-10-05T20:04:28.171Z",
      "location_count": 1,
      "location_summary": "Conshohocken, Pennsylvania",
      "locations": [
        {
          "city": "Conshohocken",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00851734"
    },
    {
      "nct_id": "NCT02194400",
      "title": "Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "RSLV-132",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Resolve Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 32,
      "start_date": "2014-07",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2015-12-09",
      "last_synced_at": "2026-10-05T20:04:28.171Z",
      "location_count": 4,
      "location_summary": "Clearwater, Florida • Grand Rapids, Michigan • Duncansville, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Duncansville",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02194400"
    }
  ]
}